269 related articles for article (PubMed ID: 1504732)
1. Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1992 May; 106(1):61-6. PubMed ID: 1504732
[TBL] [Abstract][Full Text] [Related]
2. The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.
Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1995 Jan; 114(2):339-48. PubMed ID: 7881733
[TBL] [Abstract][Full Text] [Related]
3. Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.
D'Amato M; Stamford IF; Bennett A
Br J Pharmacol; 1991 Feb; 102(2):391-5. PubMed ID: 2015421
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
Taniguchi H; Yazaki N; Endo T; Nagasaki M
Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597
[TBL] [Abstract][Full Text] [Related]
5. [Effect of cholecystokinin and its antagonists lorglumide, devazepide, and L-365,260 on gastrointestinal motility in rats].
Wang SX
Zhongguo Yao Li Xue Bao; 1993 Sep; 14(5):443-6. PubMed ID: 8010038
[TBL] [Abstract][Full Text] [Related]
6. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
Boyle SJ; Tang KW; Woodruff GN; McKnight AT
Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
[TBL] [Abstract][Full Text] [Related]
7. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor.
Yule DI; Williams JA
Peptides; 1994; 15(6):1045-51. PubMed ID: 7527529
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
[TBL] [Abstract][Full Text] [Related]
9. 2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist.
Hull RA; Shankley NP; Harper EA; Gerkowitch VP; Black JW
Br J Pharmacol; 1993 Mar; 108(3):734-40. PubMed ID: 7682135
[TBL] [Abstract][Full Text] [Related]
10. Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
van der Bent A; Blommaert AG; Melman CT; IJzerman AP; van Wijngaarden I; Soudijn W
J Med Chem; 1992 Mar; 35(6):1042-9. PubMed ID: 1552499
[TBL] [Abstract][Full Text] [Related]
11. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
Gully D; Fréhel D; Marcy C; Spinazzé A; Lespy L; Neliat G; Maffrand JP; Le Fur G
Eur J Pharmacol; 1993 Feb; 232(1):13-9. PubMed ID: 7681406
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
Ballaz S; Barber A; Fortuño A; Del Río J; Martin-Martínez M; Gómez-Monterrey I; Herranz R; González-Muñiz R; García-López MT
Br J Pharmacol; 1997 Jun; 121(4):759-67. PubMed ID: 9208145
[TBL] [Abstract][Full Text] [Related]
13. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M
Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the receptors and mechanisms involved in the cardiovascular actions of sCCK-8 in the pithed rat.
Gaw AJ; Hills DM; Spraggs CF
Br J Pharmacol; 1995 Jun; 115(4):660-4. PubMed ID: 7582487
[TBL] [Abstract][Full Text] [Related]
16. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
[TBL] [Abstract][Full Text] [Related]
17. Different effects of CCK antagonists on gastric-acid response to CCK and pentagastrin.
Corwin RL; Smith GP
Peptides; 1993; 14(2):253-7. PubMed ID: 8483804
[TBL] [Abstract][Full Text] [Related]
18. CCK-A antagonists: which and how.
D'Amato M; Rovati LC
Eur J Clin Invest; 1995 Mar; 25(3):213-4. PubMed ID: 7781670
[No Abstract] [Full Text] [Related]
19. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M
Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413
[TBL] [Abstract][Full Text] [Related]
20. CCK receptor antagonism by loxiglumide and gall bladder contractions in response to cholecystokinin, sham feeding and ordinary feeding in man.
Konturek JW; Konturek SJ; Kurek A; Bogdal J; Oleksy J; Rovati L
Gut; 1989 Aug; 30(8):1136-42. PubMed ID: 2767511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
